Summary A brief description is given of leprosy control proj ects in Orissa, Madhya Pradesh and Tamil Nadu, set up by the Government of India and assisted by the Danish International Development Agency (DANIDA), as part of the Indian National Leprosy Eradication Programme. In view of. the crucial importance of assuring the highest possible compliance to prescribed medication and regularity of clinic attendance over adequate periods of time, it was decided to use blister calendar packs for the dispensing of antileprosy drugs to patients with both paucibacillary and multi bacillary fo rms of the disease . The projects cover a population of 12 million people with an estimated 130,000 leprosy patients. The packs are being manufactured by Pharmanova, Denmark, and over the next 4-5 years, approximately 1·7 million will be used in the fo ur project areas.
In India, leprosy has been recognized as one of the fo remost public health problems with fa r-reaching socio-economic implications. l It has been estimated that there are about 4 million leprosy patients in India, 20% of whom are infectious. Nearly 58% of the Indian population live in areas with a prevalence rate of over 5 per 1000 and are considered to be at high risk of contracting the disease. 2 The Government of India has expressed a clear and indisputable political determination to control leprosy and to ultimately eradicate it by the 250 G D Georgiev and R W Kielstrup turn of the century. During the past decade the expenditure on the National Leprosy Eradication Programme (NLEP) has been increased more than 14 times and its infrastructure and the facilities expanded to a great extent. 3 Multidrug therapy for leprosy, both paucibacillary and multi bacillary, has been introduced in a phased manner in the hyperendemic districts and it is expected that the WHO multidrug regimens 4 will become standard treatment fo r leprosy by 1995.2 In this rapid expansion of the multidrug treatment (MDT) programme, NLEP has established a close and most productive cooperation with the Voluntary Leprosy Agencies and the other International Organizations (WHO/SIDA/UNICEF / DANIDA). During the period 1982-86, 15 hyperendemic districts with preva lence of more than 10 per 1000 were brought under the umbrella of MDT and most of them have shown very encouraging results. 2 , 10 .
The introduction of multiple drug therapy in leprosy control, particularly when on a large scale, necessitates a revision of the operational methodology adopted by monotherapy and the development of new strategies. 5 The need fo r efficient planning, management and monitoring, adequate infrastructure, appro priate training and active community involvement should now be widely accepted as being of crucial importance in leprosy control programmes. The operational strategy includes the origination, development, application and the evaluation of new technology to increase the effectiveness of control activities. 5 , 6 An important initiative in this direction has recently been taken by NLEP and assisted by the Danish International Development Agency (DANIDA). Four district MDT leprosy control projects have been set up, one each in Orissa and Tamil Nadu States, and two in Madhya Pradesh State, to monitor closely the whole range of control activities and to introduce and evaluate new control methodologies and technologies. These DANIDA-assisted projects cover a population of 12 million people and will take care of an estimated 130,000 leprosy patients. 7 The effectiveness of the multiple drug therapy, and for that matter the effectiveness of leprosy control, crucially depends on the proper organization of leprosy clinics (treatment points), regular clinic attendance, compliance with domiciliary treatment and the constant availability of the necessary drugs in the field. This had been recognized and taken into account at an early stage of the projects' planning and particular attention had to be paid to drug supplies, the handling of antileprosy drugs by staff and their distribution to patients. It has been suggested that blister or calendar packs would be of value in the implementation of multiple drug therapy in leprosy (and possibly also in tuberculosis). 9 It was decided to dispense the drugs fo r the treatment of multibacillary as well as paucibacilliary patients in the above projects in blister calendar packs (BCP). 7 The rationale for their use, the possible operational advantages they may offer, the design requirements and the operational methodology are discussed in a separate pUblication. 8 The object of the present communication is to describe the design, structure and technical specifications of the packs which are developed and are to be used for both paucibacillary and 25 1 multibacillary leprosy patients in India. We hope that such information may be of benefit to others who are engaged in the treatment of leprosy patients and the control of leprosy, using WHO-recommended multidrug regimens.
Design and structure of BCP's Separate BCP's for multibacillary (MB) and paucibacillary (PB) cases have been designed and it is expected that 1,7 million packs will be produced by Pharmanova in Copenhagen and used over a period of 4-5 years in the treatment of both adult and child patients. As the number of children who suffer from MB fo rms of leprosy is relatively low, it has not been cost-effective to produce BCP's fo r them and they will be treated with 'loose' tablets and capsules.
The initial design of a BCP requires careful consideration, since the capital outlay may be considerable. Combining one tablet and three other differently shaped products into one pack requires high technology and precision packing machinery. Changes in the design after field trials are also not easily undertaken because of the high cost of re-tooling for multiple product blisters. The pack design described here attempts to combine ease of handling fo r health staff with clarity and convenience fo r the patient. The upper part of the BCP contains the supervised clinic (or treatment point) dose of 2 capsules of rifampicin, each of 300 mg; 3 capsules of clofazimine, each of 100 mg; and I tablet of dapsone 100 mg (see Figures I and 2 ). After dispensing the drugs, the top of the pack is torn away along the perforated line and the rest of the pack containing the domiciliary treatment is given to the patient. The remaining pack can be fo lded vertically down the middle, thus protecting the vulnerable side of the aluminium fo il and reducing the size. The arrangement of the drugs fo r home treatment is based on the lunar month in fo ur weekly rows, making it easy fo r the pati e nt to take his daily dose and for the staff to check the patient's compliance during home visits or at the clinic.
The MB-adult blister pack measures 122 mm x 146 m, Figures 1 and 2. After the top part is torn off at the clinic, the size of the remainder of the pack for home use measures 122 mm x 119 mm. This part fo lds along the middle, further reducing the size to 61 mm x 119 mm, so that the pack can easily be carried in the shirt pocket by the patient. The PB pack (Figure 3 ) measures 72 x 122 mm. After detaching the part for the monthly dose, it can also be fo lded to reduce the size.
The materials of which the BCP are made should provide optimal protection fo r the drugs against humidity and moisture, light and accidental physical damage. The blister body of the BCP is made of high-barrier tropicalized triplex laminate (TTL), a clear, rigid, triple layer of 328 micron thickness PVc. TTL has a weight of 46 1 g/m 2 , which is considerably higher than the conventional mono PVC, giving optimal moisture protection for use in tropical conditions and adding extra strength and stability to the relatively large fo rmat blister packs.
The body of the blister pack is backed with a moisture impervious, 20 micron, aluminium fo il covering. The protection against humidity and moisture is fu rther enhanced by one layer of a heavily reinforced PVdC, resulting in significantly improved barrier protection fo r the TTL, having a moisture vapour transmission rate (MVTR) of 0·06 gjm 2 j24 h under tropical conditions of 38°C and 90% relative humidity. This compares very fa vourably with conventional mono PVC 250 micron, the MVTR rate fo r which is 3·1 gjm 2 j24 h. (DIN 53122) or approximately 5 times that of the TTL. Under less rigorous storage conditions of 20°Cj85% rh., the MVTR rate of the TLL is as low as 0·07 gjm 2 j24 h. The MVTR rates given are those of the finished blister, i.e. after standard thermoforming. The light protective (and child resistant) properties of the calendar blister could be enhanced by employing fully coloured or white opaque laminate, but this should be weighed against the disadvantage of obscuring the blister contents from the view of patients having no prior experience or dexterity in the handling of such packs.
MULTIPLE DRUG THERAPY (MDT) FOR LEPROSY MUL TIBACILLARY (MB) -ADULT CALENDAR PACK (BLISTER)
The packs fo r these projects in India have been produced in three different colours: red for adult MB cases, green for adult PB cases and blue for child PB cases (no pack has been produced for child MB cases for the reasons already stated). It is also intended to provide written directions for patients and staff, on paper of corresponding colours; thus the clinical grouping into PB or MB, the drug regimen and the directions fo r use, will be clearly linked. Finally, it is also intended to give each patient a non-transparent PVC pack holder which will provide additional protection against moisture, light and physical damage. This will accommodate the pack itself, the instructions and the patient's identification/ treatment card, whilst at the same time affording a degree of privacy for those who are sensitive about the association of BCP's with leprosy.
The operational benefits and cost-effectiveness of BCP's in the treatment of leprosy have yet to be defined . However, in view of the limited number of drugs currently available fo r the treatment of this disease and the extreme importance of assuring compliance to prescribed regimens, together with regularity of attend ance for adequate periods of time, many avenues must be explored. What appears at first consideration to be expensive and inappropriate may, in the long run, be of decisive value. We hope that this communication will provide useful information to those who wish to consider this approach in the implementation of MDT in leprosy. Teaching included presentations on basic anatomy, physiology and pathology of the eye with special emphasis on leprosy; in addition there were lectures on the clinical signs and management of lagophthalmos, intra-ocular inflammation, corneal ulcers and infiltrative lesions together with a discussion on global aspects of blindness in leprosy.
NE WS AND NO TES
There were twelve participants on the course which was sponsored jointly by the Christoffel Blindenmission and LEPRA who together with the staff of Karigiri and The Leprosy Mission are to be congratulated on their support for this important contribution to teaching. Further enquiries: Mr T ffy tche, Consultant Ophthalmolo gist, Department of Ophthalmology, St Thomas's Hospital, Lambeth Palace Road, London SE I 7EH.
